Merck KGaA, Darmstadt, Germany, through its wholly owned subsidiary, Ares Trading, amended its agreement with Intrexon Corp. for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. The agreement with Intrexon and its wholly-owned subsidiary, Precigen, Inc., enables Merck KGaA to continue to implement its R&D strategy, while maintaining an investment in the future potential of next-gen CAR-T development. Merck KGaA will assign its exclusive CAR-T development rights to ...